Short-term interest in PureTech Health plc (NASDAQ:PRTC) drops 32.1%

PureTech Health plc (NASDAQ: PRTC – Get a rating) was the target of a significant drop in short interest in July. As of July 15, there was short interest totaling 1,900 shares, down 32.1% from the June 30 total of 2,800 shares. Based on an average daily volume of 5,500 shares, the day-to-cover ratio is currently 0.3 days.

PureTech Health Price Performance

NASDAQ PRTC shares traded at $0.91 during Friday trading hours, hitting $24.64. The stock recorded trading volume of 2,039 shares, compared to an average trading volume of 4,419 shares. The company has a debt ratio of 0.02, a quick ratio of 2.22 and a current ratio of 2.22. The company’s fifty-day moving average is $22.24 and its two-hundred-day moving average is $26.72. PureTech Health has a 12-month low of $18.15 and a 12-month high of $56.46.

Analysts set new price targets

A number of research analysts have recently commented on the company. Piper Sandler set a target price of $37.00 on PureTech Health in a Monday, June 20 research note. SVB Leerink reduced its target price on PureTech Health from $70.00 to $66.00 and set an “outperform” rating for the company in a Wednesday, June 15 research note.

About PureTech Health

(Get a rating)

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops and markets drugs for inflammatory, fibrotic and immunological, incurable, lymphatic and gastrointestinal, neurological and neuropsychological cancers, and other diseases in the United States. The Company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer’s disease; a regenerative biology platform for androgenetic alopecia, epithelial aging and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria are isolated from the human microbiome; and therapies to treat cognitive dysfunctions associated with depression, multiple sclerosis, post-COVID and critical care, and cancer-related conditions.

Featured articles

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in PureTech Health right now?

Before you consider PureTech Health, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and PureTech Health wasn’t on the list.

Although PureTech Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Comments are closed.